Organization
Xiangya Hospital of Central South University, Changsha, China
7 abstracts
Abstract
PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM).Org: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Guizhou Cancer Hospital, Guiyang, China, Affiliated Tumor Hospital of Guangxi Medical University, Guangxi, China, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Xijing Hospital, Xi'an, China,
Abstract
High-dose almonertinib in treatment-naïve EGFR-mutated NSCLC with CNS metastases: Efficacy and biomarker analysis.Org: Zhejiang Cancer Hospital, Hangzhou Yirui Pharmaceutical Technology, China National Biotec Group, Zhejiang Hospital, Department of Thoracic Medical Oncology,
Abstract
Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.Org: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer,
Abstract
Identification of molecular subtypes for integrated multi-omics analysis for use in guiding precision medicine in hepatocellular carcinoma.Org: Xiangya Hospital of Central South University, Changsha, China, Changsha, Hunan Center hospital, China National Biotec Group,
Abstract
Neoadjuvant immunotherapy-driven bladder preservation for muscle-invasive bladder cancer: A multicenter, propensity score-matched cohort study.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Xiangya Hospital of Central South University, Changsha, China, Central South University, Changsha, China,
Abstract
Efficacy and safety of neoadjuvant therapy with disitamab vedotin plus toripalimab in treating muscle invasive urothelial bladder cancer followed by selective bladder-preserving or radical cystectomy.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Xiangya Hospital of Central South University, Changsha, China, Central South University, Changsha, China,
Abstract
The safety and efficacy of immune checkpoint inhibitor in combination with FOLFOX as neoadjuvant/adjuvant therapy in patients with locally advanced colon cancer.Org: Xiangya Hospital of Central South University, Changsha, China, Changsha, China National Biotec Group, Central South University, Hunan Center hospital,